Background:
Benefits of prophylactic hematopoietic colony-stimulating factors (CSFs) in adults and children receiving cancer chemotherapy or undergoing stem-cell transplantation (SCT) are unclear.
Purpose:
To determine whether prophylactic CSFs decrease mortality, infections, and febrile neutropenia more than does placebo or no therapy in patients with cancer and in patients undergoing SCT.
Data Sources:
Electronic searches of Ovid MEDLINE and EMBASE from inception until April 2007 and of the Cochrane Central Register of Controlled Trials until the second quarter of 2006.
Study Selection:
We selected 148 trials that were reported in any language that randomly assigned patients to CSFs or to either placebo or no therapy. Prophylactic CSFs were given concurrently with or after initiation of chemotherapy.
Data Extraction:
Two reviewers independently extracted data onto standardized forms.
Data Synthesis:
Short-term all-cause mortality appeared to be similar between the prophylactic CSF and the control groups (7.6% vs. 8.0%; relative risk, 0.95 [95% CI, 0.84 to 1.08]; absolute risk reduction, 0.4% [CI, −0.5% to 1.4%]). Risks for infection-related death with CSFs and placebo or no therapy were 3.1% and 3.8%, respectively (relative risk, 0.82 [CI, 0.66 to 1.02]; absolute risk reduction, 0.8% [CI, 0.0% to 1.5%]). Use of CSFs reduced the following more than did placebo or no therapy: documented infections (median rate, 38.9% vs. 43.1%; rate ratio, 0.85 [CI, 0.79 to 0.92]), microbiologically documented infections (median rate, 23.5% vs. 28.6%; rate ratio, 0.86 [CI, 0.77 to 0.96]), and episodes of febrile neutropenia (median rate, 25.3% vs. 44.2%; rate ratio, 0.71 [CI, 0.63 to 0.80]).
Limitations:
Trial designs, including assessments of infections, and participants were heterogeneous. Estimates of mortality effects were imprecise.
Conclusions:
Prophylactic CSFs may have little or no effect on mortality but do decrease rates of infection in patients receiving cancer chemotherapy or those undergoing SCT.
References
- 1.
Lehrnbecher T ,Welte K . Haematopoietic growth factors in children with neutropenia. Br J Haematol. 2002;116:28-56. [PMID:11841397 ] CrossrefMedlineGoogle Scholar - 2.
American Society of Clinical Oncology . Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 1994;12:2471-508. [PMID:7964965 ] CrossrefMedlineGoogle Scholar - 3.
Lyman GH ,Kuderer NM ,Djulbegovic B . Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112:406-11. [PMID:11904116 ] CrossrefMedlineGoogle Scholar - 4.
Bohlius J ,Reiser M ,Schwarzer G ,Engert A . Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol. 2003;122:413-23. [PMID:12877668 ] CrossrefMedlineGoogle Scholar - 5.
Bohlius J ,Reiser M ,Schwarzer G ,Engert A . Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev. 2004;:CD003189. [PMID:15266474 ] MedlineGoogle Scholar - 6.
Berghmans T ,Paesmans M ,Lafitte JJ ,Mascaux C ,Meert AP ,Sculier JP . Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer. 2002;37:115-23. [PMID:12140132 ] CrossrefMedlineGoogle Scholar - 7.
Sung L ,Nathan PC ,Lange B ,Beyene J ,Buchanan GR . Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized, controlled trials. J Clin Oncol. 2004;22:3350-6. [PMID:15310780 ] CrossrefMedlineGoogle Scholar - 8.
Sasse EC ,Sasse AD ,Brandalise S ,Clark OA ,Richards S . Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2005;:CD004139. [PMID:16034921 ] MedlineGoogle Scholar - 9.
Dekker A ,Bulley S ,Beyene J ,Dupuis LL ,Doyle JJ ,Sung L . Meta-analysis of randomized, controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol. 2006;24:5207-15. [PMID:17114653 ] CrossrefMedlineGoogle Scholar - 10.
Moher D ,Cook DJ ,Eastwood S ,Olkin I ,Rennie D ,Stroup DF . Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354:1896-900. [PMID:10584742 ] CrossrefMedlineGoogle Scholar - 11.
Landis JR ,Koch GG . The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-74. [PMID:843571 ] CrossrefMedlineGoogle Scholar - 12.
Jadad AR ,Moore RA ,Carroll D ,Jenkinson C ,Reynolds DJ ,Gavaghan DJ ,et al . Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12. [PMID:8721797 ] CrossrefMedlineGoogle Scholar - 13.
Bieler GS ,Williams RL . Ratio estimates, the delta method, and quantal response tests for increased carcinogenicity. Biometrics. 1993;49:793-801. [PMID:8241374 ] CrossrefMedlineGoogle Scholar - 14.
DerSimonian R ,Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. [PMID:3802833 ] CrossrefMedlineGoogle Scholar - 15.
Sutton AJ ,Duval SJ ,Tweedie RL ,Abrams KR ,Jones DR . Empirical assessment of effect of publication bias on meta-analyses. BMJ. 2000;320:1574-7. [PMID:10845965 ] CrossrefMedlineGoogle Scholar - 16.
Ohno R ,Tomonaga M ,Kobayashi T ,Kanamaru A ,Shirakawa S ,Masaoka T ,et al . Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med. 1990;323:871-7. [PMID:1697646 ] CrossrefMedlineGoogle Scholar - 17.
Crawford J ,Ozer H ,Stoller R ,Johnson D ,Lyman G ,Tabbara I ,et al . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-70. [PMID:1711156 ] CrossrefMedlineGoogle Scholar - 18.
Kaplan LD ,Kahn JO ,Crowe S ,Northfelt D ,Neville P ,Grossberg H ,et al . Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol. 1991;9:929-40. [PMID:2033429 ] CrossrefMedlineGoogle Scholar - 19.
Nemunaitis J ,Rabinowe SN ,Singer JW ,Bierman PJ ,Vose JM ,Freedman AS ,et al . Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324:1773-8. [PMID:1903847 ] CrossrefMedlineGoogle Scholar - 20.
De Witte T ,Gratwohl A ,Van Der Lely N ,Bacigalupo A ,Stern AC ,Speck B ,et al . Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood. 1992;79:1359-65. [PMID:1536959 ] CrossrefMedlineGoogle Scholar - 21.
Gorin NC ,Coiffier B ,Hayat M ,Fouillard L ,Kuentz M ,Flesch M ,et al . Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial. Blood. 1992;80:1149-57. [PMID:1515637 ] CrossrefMedlineGoogle Scholar - 22.
Gulati SC ,Bennett CL . Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med. 1992;116:177-82. [PMID:1728202 ] LinkGoogle Scholar - 23.
Khwaja A ,Linch DC ,Goldstone AH ,Chopra R ,Marcus RE ,Wimperis JZ ,et al . Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double-blind, placebo-controlled trial. Br J Haematol. 1992;82:317-23. [PMID:1419813 ] CrossrefMedlineGoogle Scholar - 24.
Link H ,Boogaerts MA ,Carella AM ,Ferrant A ,Gadner H ,Gorin NC ,et al . A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood. 1992;80:2188-95. [PMID:1421390 ] CrossrefMedlineGoogle Scholar - 25.
Pettengell R ,Gurney H ,Radford JA ,Deakin DP ,James R ,Wilkinson PM ,et al . Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized, controlled trial. Blood. 1992;80:1430-6. [PMID:1381626 ] CrossrefMedlineGoogle Scholar - 26.
De Witte T ,Vreugdenhil G ,Schattenberg A . Prolonged administration of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) after T-cell-depleted allogeneic bone marrow transplantation. Transplant Proc. 1993;25:57-60. [PMID:8351721 ] MedlineGoogle Scholar - 27.
Gerhartz HH ,Engelhard M ,Meusers P ,Brittinger G ,Wilmanns W ,Schlimok G ,et al . Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood. 1993;82:2329-39. [PMID:7691256 ] CrossrefMedlineGoogle Scholar - 28.
Linch DC ,Scarffe H ,Proctor S ,Chopra R ,Taylor PR ,Morgenstern G ,et al . Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant. 1993;11:307-11. [PMID:7683552 ] MedlineGoogle Scholar - 29.
Shaffer DW ,Smith LS ,Burris HA ,Clark GM ,Eckardt JR ,Fields SM ,et al . A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies. Cancer Res. 1993;53:5929-33. [PMID:8261405 ] MedlineGoogle Scholar - 30.
Avilés A ,Díaz-Maqueo JC ,Talavera A ,Nambo MJ ,García EL . Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy. Leuk Lymphoma. 1994;15:153-7. [PMID:7532056 ] CrossrefMedlineGoogle Scholar - 31.
Calderwood S ,Romeyer F ,Blanchette V ,Chan H ,Doyle J ,Greenberg M ,et al . Concurrent RhGM-CSF does not offset myelosuppression from intensive chemotherapy: randomized placebo-controlled study in childhood acute lymphoblastic leukemia. Am J Hematol. 1994;47:27-32. [PMID:8042612 ] CrossrefMedlineGoogle Scholar - 32.
Gisselbrecht C ,Prentice HG ,Bacigalupo A ,Biron P ,Milpied N ,Rubie H ,et al . Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet. 1994;343:696-700. [PMID:7510813 ] CrossrefMedlineGoogle Scholar - 33.
Miles DW ,Fogarty O ,Ash CM ,Rudd RM ,Trask CW ,Spiro SG ,et al . Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol. 1994;12:77-82. [PMID:7505809 ] CrossrefMedlineGoogle Scholar - 34.
Stahel RA ,Jost LM ,Cerny T ,Pichert G ,Honegger H ,Tobler A ,et al . Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol. 1994;12:1931-8. [PMID:7521907 ] CrossrefMedlineGoogle Scholar - 35.
Bajorin DF ,Nichols CR ,Schmoll HJ ,Kantoff PW ,Bokemeyer C ,Demetri GD ,et al . Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. J Clin Oncol. 1995;13:79-86. [PMID:7799046 ] CrossrefMedlineGoogle Scholar - 36.
Bui BN ,Chevallier B ,Chevreau C ,Krakowski I ,Peny AM ,Thyss A ,et al . Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol. 1995;13:2629-36. [PMID:7595717 ] CrossrefMedlineGoogle Scholar - 37.
Bunn PA ,Crowley J ,Kelly K ,Hazuka MB ,Beasley K ,Upchurch C ,et al . Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol. 1995;13:1632-41. [PMID:7602352 ] CrossrefMedlineGoogle Scholar - 38.
Dombret H ,Chastang C ,Fenaux P ,Reiffers J ,Bordessoule D ,Bouabdallah R ,et al . A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med. 1995;332:1678-83. [PMID:7539109 ] CrossrefMedlineGoogle Scholar - 39.
Klumpp TR ,Mangan KF ,Goldberg SL ,Pearlman ES ,Macdonald JS . Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol. 1995;13:1323-7. [PMID:7538555 ] CrossrefMedlineGoogle Scholar - 40.
Nemunaitis J ,Rosenfeld CS ,Ash R ,Freedman MH ,Deeg HJ ,Appelbaum F ,et al . Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:949-54. [PMID:7581096 ] MedlineGoogle Scholar - 41.
Ottmann OG ,Hoelzer D ,Gracien E ,Ganser A ,Kelly K ,Reutzel R ,et al . Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood. 1995;86:444-50. [PMID:7541660 ] CrossrefMedlineGoogle Scholar - 42.
Riikonen P ,Rahiala J ,Salonvaara M ,Perkkiö M . Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer. Stem Cells. 1995;13:289-94. [PMID:7542114 ] CrossrefMedlineGoogle Scholar - 43.
Rowe JM ,Andersen JW ,Mazza JJ ,Bennett JM ,Paietta E ,Hayes FA ,et al . A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86:457-62. [PMID:7605984 ] CrossrefMedlineGoogle Scholar - 44.
Schmitz N ,Dreger P ,Zander AR ,Ehninger G ,Wandt H ,Fauser AA ,et al . Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant. 1995;15:261-6. [PMID:7539668 ] MedlineGoogle Scholar - 45.
Seymour AM ,de Campos E ,Thatcher N ,De Greve J ,Cunningham D ,Howell A ,et al . A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma. Eur J Cancer. 1995;31A:2157-63. [PMID:8652235 ] CrossrefMedlineGoogle Scholar - 46.
Stone RM ,Berg DT ,George SL ,Dodge RK ,Paciucci PA ,Schulman P ,et al . Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995;332:1671-7. [PMID:7760868 ] CrossrefMedlineGoogle Scholar - 47.
Takeshita A ,Ohno R ,Hirashima K ,Toyama K ,Okuma M ,Saito H ,et al . [A randomized double-blind controlled study of recombinant human granulocyte colony-stimulating factor in patients with neutropenia induced by consolidation chemotherapy for acute myeloid leukemia. (rG.CSF clinical study group)]. Rinsho Ketsueki. 1995;36:606-14. [PMID:7543956 ] MedlineGoogle Scholar - 48.
Woll PJ ,Hodgetts J ,Lomax L ,Bildet F ,Cour-Chabernaud V ,Thatcher N . Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized, controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol. 1995;13:652-9. [PMID:7533825 ] CrossrefMedlineGoogle Scholar - 49.
Greenberg P ,Advani R ,Keating A ,Gulati SC ,Nimer S ,Champlin R ,et al . GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 1996;18:1057-64. [PMID:8971373 ] MedlineGoogle Scholar - 50.
Jones SE ,Schottstaedt MW ,Duncan LA ,Kirby RL ,Good RH ,Mennel RG ,et al . Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. J Clin Oncol. 1996;14:2976-83. [PMID:8918495 ] CrossrefMedlineGoogle Scholar - 51.
Weiss GR ,Shaffer DW ,DeMoor C ,Rinaldi DA ,Rodriguez GI ,Eckardt JR ,et al . A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer. Anticancer Drugs. 1996;7:402-9. [PMID:8826608 ] CrossrefMedlineGoogle Scholar - 52.
Wexler LH ,Weaver-McClure L ,Steinberg SM ,Jacobson J ,Jarosinski P ,Avila N ,et al . Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. J Clin Oncol. 1996;14:901-10. [PMID:8622038 ] CrossrefMedlineGoogle Scholar - 53.
Yau JC ,Neidhart JA ,Triozzi P ,Verma S ,Nemunaitis J ,Quick DP ,et al . Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin. Am J Hematol. 1996;51:289-95. [PMID:8602629 ] CrossrefMedlineGoogle Scholar - 54.
Zittoun R ,Suciu S ,Mandelli F ,de Witte T ,Thaler J ,Stryckmans P ,et al . Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol. 1996;14:2150-9. [PMID:8683249 ] CrossrefMedlineGoogle Scholar - 55.
Fridrik MA ,Greil R ,Hausmaninger H ,Krieger O ,Oppitz P ,Stöger M ,et al . Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy. Ann Hematol. 1997;75:135-40. [PMID:9402845 ] MedlineGoogle Scholar - 56.
Fukuoka M ,Masuda N ,Negoro S ,Matsui K ,Yana T ,Kudoh S ,et al . CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer. 1997;75:306-9. [PMID:9010043 ] CrossrefMedlineGoogle Scholar - 57.
Geissler K ,Koller E ,Hubmann E ,Niederwieser D ,Hinterberger W ,Geissler D ,et al . Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia—a randomized phase-III study. Blood. 1997;90:590-6. [PMID:9226158 ] CrossrefMedlineGoogle Scholar - 58.
Gisselbrecht C ,Haioun C ,Lepage E ,Bastion Y ,Tilly H ,Bosly A ,et al . Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma. 1997;25:289-300. [PMID:9168439 ] MedlineGoogle Scholar - 59.
Heil G ,Hoelzer D ,Sanz MA ,Lechner K ,Liu Yin JA ,Papa G ,et al . A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood. 1997;90:4710-8. [PMID:9389686 ] CrossrefMedlineGoogle Scholar - 60.
Legros M ,Fleury J ,Bay JO ,Choufi B ,Basile M ,Condat P ,et al . rhGM-CSF vs placebo following rhGM-CSF-mobilized PBPC transplantation: a phase III double-blind randomized trial. Bone Marrow Transplant. 1997;19:209-13. [PMID:9028547 ] CrossrefMedlineGoogle Scholar - 61.
Linch DC ,Milligan DW ,Winfield DA ,Kelsey SM ,Johnson SA ,Littlewood TJ ,et al . G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol. 1997;99:933-8. [PMID:9432046 ] CrossrefMedlineGoogle Scholar - 62.
Löwenberg B ,Boogaerts MA ,Daenen SM ,Verhoef GE ,Hagenbeek A ,Vellenga E ,et al . Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol. 1997;15:3496-506. [PMID:9396403 ] CrossrefMedlineGoogle Scholar - 63.
Moreau P ,Fiere D ,Bezwoda WR ,Facon T ,Attal M ,Laporte JP ,et al . Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma. J Clin Oncol. 1997;15:660-6. [PMID:9053491 ] CrossrefMedlineGoogle Scholar - 64.
Pui CH ,Boyett JM ,Hughes WT ,Rivera GK ,Hancock ML ,Sandlund JT ,et al . Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med. 1997;336:1781-7. [PMID:9187068 ] CrossrefMedlineGoogle Scholar - 65.
Bernasconi C ,Alessandrino EP ,Bernasconi P ,Bonfichi M ,Lazzarino M ,Canevari A ,et al . Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. Br J Haematol. 1998;102:678-83. [PMID:9722293 ] CrossrefMedlineGoogle Scholar - 66.
Fosså SD ,Kaye SB ,Mead GM ,Cullen M ,de Wit R ,Bodrogi I ,et al . Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol. 1998;16:716-24. [PMID:9469362 ] MedlineGoogle Scholar - 67.
Godwin JE ,Kopecky KJ ,Head DR ,Willman CL ,Leith CP ,Hynes HE ,et al . A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood. 1998;91:3607-15. [PMID:9572995 ] CrossrefMedlineGoogle Scholar - 68.
Hidalgo M ,Mendiola C ,López-Vega JM ,Castellano D ,Mendez M ,Batiste-Alenton E ,et al . A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain. Cancer. 1998;83:719-25. [PMID:9708936 ] CrossrefMedlineGoogle Scholar - 69.
Larson RA ,Dodge RK ,Linker CA ,Stone RM ,Powell BL ,Lee EJ ,et al . A randomized, controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92:1556-64. [PMID:9716583 ] MedlineGoogle Scholar - 70.
Michon JM ,Hartmann O ,Bouffet E ,Meresse V ,Coze C ,Rubie H ,et al . An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. Eur J Cancer. 1998;34:1063-9. [PMID:9849455 ] CrossrefMedlineGoogle Scholar - 71.
Steward WP ,von Pawel J ,Gatzemeier U ,Woll P ,Thatcher N ,Koschel G ,et al . Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol. 1998;16:642-50. [PMID:9469353 ] CrossrefMedlineGoogle Scholar - 72.
Witz F ,Sadoun A ,Perrin MC ,Berthou C ,Brière J ,Cahn JY ,et al . A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). Blood. 1998;91:2722-30. [PMID:9531581 ] MedlineGoogle Scholar - 73.
Clarke V ,Dunstan FD ,Webb DK . Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia. Med Pediatr Oncol. 1999;32:331-5. [PMID:10219333 ] CrossrefMedlineGoogle Scholar - 74.
Ifrah N ,Witz F ,Jouet JP ,François S ,Lamy T ,Linassier C ,et al . Intensive short term therapy with granulocyte–macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. GOELAMS Group. Cancer. 1999;86:1496-505. [PMID:10526278 ] CrossrefMedlineGoogle Scholar - 75.
Ohno R ,Mizoguchi H ,Tomonaga M ,Aoki N ,Takaku F . A randomized, controlled study of rhG-CSF (KW-2228) in patients with neutropenia induced by chemotherapy in acute leukemia. Biotherapy. 1999;13:701-9. Google Scholar - 76.
Ojeda E ,Garcia-Bustos J ,Aguado M ,Arrieta R ,Quevedo E ,Yuste VJ ,et al . A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults. Bone Marrow Transplant. 1999;24:601-7. [PMID:10490724 ] CrossrefMedlineGoogle Scholar - 77.
Thomas X ,Fenaux P ,Dombret H ,Delair S ,Dreyfus F ,Tilly H ,et al . Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia. 1999;13:1214-20. [PMID:10450749 ] MedlineGoogle Scholar - 78.
Bishop MR ,Tarantolo SR ,Geller RB ,Lynch JC ,Bierman PJ ,Pavletic ZS ,et al . A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood. 2000;96:80-5. [PMID:10891434 ] CrossrefMedlineGoogle Scholar - 79.
Harousseau JL ,Witz B ,Lioure B ,Hunault-Berger M ,Desablens B ,Delain M ,et al . Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aiguës Myéloblastiques. J Clin Oncol. 2000;18:780-7. [PMID:10673519 ] CrossrefMedlineGoogle Scholar - 80.
Michel G ,Landman-Parker J ,Auclerc MF ,Mathey C ,Leblanc T ,Legall E ,et al . Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18:1517-24. [PMID:10735900 ] CrossrefMedlineGoogle Scholar - 81.
Pfreundschuh M ,Hasenclever D ,Loeffler M ,Ehninger G ,Schmitz N ,Kirchner H ,et al ;German Hodgkin's Lymphoma Study Group . Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF. Ann Oncol. 2001;12:471-7. [PMID:11398878 ] CrossrefMedlineGoogle Scholar - 82.
Przepiorka D ,Smith TL ,Folloder J ,Anderlini P ,Chan KW ,Körbling M ,et al . Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood. 2001;97:3405-10. [PMID:11369630 ] CrossrefMedlineGoogle Scholar - 83.
Channa J ,Hashmi KZ . Role of recombinant granulocyte-macrophage colony-stimulating factors in reducing the duration of neutropenia. J College Phys Surg Pakistan. 2002;12:538-41. Google Scholar - 84.
Dallorso S ,Rondelli R ,Messina C ,Pession A ,Giorgiani G ,Fagioli F ,et al . Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children: results of a prospective randomized trial. Haematologica. 2002;87:1274-80. [PMID:12495901 ] MedlineGoogle Scholar - 85.
Hołowiecki J ,Giebel S ,Krzemień S ,Krawczyk-Kuliś M ,Jagoda K ,Kopera M ,et al . G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study. Leuk Lymphoma. 2002;43:315-25. [PMID:11999563 ] CrossrefMedlineGoogle Scholar - 86.
Usuki K ,Urabe A ,Masaoka T ,Ohno R ,Mizoguchi H ,Hamajima N ,et al ;Gran AML Study Group . Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol. 2002;116:103-12. [PMID:11841402 ] CrossrefMedlineGoogle Scholar - 87.
Doorduijn JK ,van der Holt B ,van Imhoff GW ,van der Hem KG ,Kramer MH ,van Oers MH ,et al . CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:3041-50. [PMID:12915593 ] CrossrefMedlineGoogle Scholar - 88.
Schmitz N ,Ljungman P ,Cordonnier C ,Kempf C ,Linkesch W ,Alegre A ,et al . Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial. Bone Marrow Transplant. 2004;34:955-62. [PMID:15489865 ] CrossrefMedlineGoogle Scholar - 89.
Thomas X ,Boiron JM ,Huguet F ,Reman O ,Sutton L ,Turlure P ,et al ;Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group) . Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study. Hematol J. 2004;5:384-94. [PMID:15448664 ] CrossrefMedlineGoogle Scholar - 90.
Amadori S ,Suciu S ,Jehn U ,Stasi R ,Thomas X ,Marie JP ,et al ;EORTC/GIMEMA Leukemia Group . Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005;106:27-34. [PMID:15761020 ] CrossrefMedlineGoogle Scholar - 91.
Vogel CL ,Wojtukiewicz MZ ,Carroll RR ,Tjulandin SA ,Barajas-Figueroa LJ ,Wiens BL ,et al . First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178-84. [PMID:15718314 ] CrossrefMedlineGoogle Scholar - 92.
Zwierzina H ,Suciu S ,Loeffler-Ragg J ,Neuwirtova R ,Fenaux P ,Beksac M ,et al ;EORTC Leukemia Cooperative Group . Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia. 2005;19:1929-33. [PMID:16151466 ] MedlineGoogle Scholar - 93.
Burton C ,Linch D ,Hoskin P ,Milligan D ,Dyer MJ ,Hancock B ,et al . A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. Br J Cancer. 2006;94:806-13. [PMID:16508640 ] CrossrefMedlineGoogle Scholar - 94.
Milligan DW ,Wheatley K ,Littlewood T ,Craig JI ,Burnett AK ;NCRI Haematological Oncology Clinical Studies Group . Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood. 2006;107:4614-22. [PMID:16484584 ] CrossrefMedlineGoogle Scholar - 95.
Thomas X ,Raffoux E ,Botton S ,Pautas C ,Arnaud P ,de Revel T ,et al . Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia. 2007;21:453-61. [PMID:17252021 ] CrossrefMedlineGoogle Scholar - 96.
Ringdén O ,Labopin M ,Gorin NC ,Le Blanc K ,Rocha V ,Gluckman E ,et al . Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2004;22:416-23. [PMID:14691124 ] MedlineGoogle Scholar - 97.
Remberger M ,Naseh N ,Aschan J ,Barkholt L ,LeBlanc K ,Svennberg P ,et al . G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant. 2003;32:217-23. [PMID:12838288 ] CrossrefMedlineGoogle Scholar - 98.
Eapen M ,Horowitz MM ,Klein JP ,Champlin RE ,Loberiza FR ,Ringdén O ,et al . Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol. 2004;22:4872-80. [PMID:15520055 ] CrossrefMedlineGoogle Scholar - 99.
Adams JR ,Lyman GH ,Djubegovic B ,Feinglass J ,Bennett CL . G-CSF as prophylaxis of febrile neutropenia in SCLC. Expert Opin Pharmacother. 2002;3:1273-81. [PMID:12186620 ] CrossrefMedlineGoogle Scholar - 100.
Gafter-Gvili A ,Fraser A ,Paul M ,Leibovici L . Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142:979-95. [PMID:15968013 ] LinkGoogle Scholar - 101.
Smith TJ ,Khatcheressian J ,Lyman GH ,Ozer H ,Armitage JO ,Balducci L ,et al . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187-205. [PMID:16682719 ] CrossrefMedlineGoogle Scholar - 102.
Lehrnbecher T ,Zimmermann M ,Reinhardt D ,Dworzak M ,Stary J ,Creutzig U . Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood. 2007;109:936-43. [PMID:17008536 ] CrossrefMedlineGoogle Scholar - 103.
Creutzig U ,Zimmermann M ,Lehrnbecher T ,Graf N ,Hermann J ,Niemeyer CM ,et al . Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24:4499-506. [PMID:16983120 ] CrossrefMedlineGoogle Scholar - 104.
Faber E ,Pytlík R ,Slabý J ,Zapletalová J ,Kozák T ,Raida L ,et al . Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma—results of a prospective multicentre controlled trial. Eur J Haematol. 2006;77:493-500. [PMID:17042769 ] CrossrefMedlineGoogle Scholar - 105.
Kuzhan O ,Arpaci F ,Ozet A ,Ozturk B ,Komurcu S . Delayed molgramostim administration after autologous peripheral blood stem cell transplantation does not add any benefit regarding hematologic engraftment and supportive therapy requirements: A prospective randomized trial. Turkish J Cancer. 2006;36:57-63. Google Scholar - 106.
Rao R ,Shammo JM ,Enschede SH ,Porter C ,Adler SS ,Venugopal P ,et al . The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. Clin Lymphoma. 2005;6:26-30. [PMID:15989703 ] CrossrefMedlineGoogle Scholar - 107.
Timmer-Bonte JN ,de Boo TM ,Smit HJ ,Biesma B ,Wilschut FA ,Cheragwandi SA ,et al . Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol. 2005;23:7974-84. [PMID:16258098 ] CrossrefMedlineGoogle Scholar - 108.
Valteau-Couanet D ,Faucher C ,Aupérin A ,Michon J ,Milpied N ,Boiron JM ,et al . Cost effectiveness of day 5 G-CSF (lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Bone Marrow Transplant. 2005;36:547-52. [PMID:16007101 ] CrossrefMedlineGoogle Scholar - 109.
González-Vicent M ,Madero L ,Sevilla J ,Ramirez M ,Díaz MA . A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children. Bone Marrow Transplant. 2004;34:1077-81. [PMID:15516942 ] CrossrefMedlineGoogle Scholar - 110.
Wang TJ ,Liu LL ,Cheng GH ,Liu XL ,Qu YQ ,Wu ZF ,et al . [A brief report on effect of rhG-CSF in treating leukopenia after radio-and chemo-therapy of patients with breast cancer]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004;12:381-2. [PMID:15228673 ] MedlineGoogle Scholar - 111.
Grigg A ,Solal-Celigny P ,Hoskin P ,Taylor K ,McMillan A ,Forstpointner R ,et al ;International Study Group . Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 2003;44:1503-8. [PMID:14565651 ] CrossrefMedlineGoogle Scholar - 112.
Heath JA ,Steinherz PG ,Altman A ,Sather H ,Jhanwar S ,Halpern S ,et al ;Children's Cancer Group . Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study. J Clin Oncol. 2003;21:1612-7. [PMID:12697887 ] CrossrefMedlineGoogle Scholar - 113.
Papaldo P ,Lopez M ,Cortesi E ,Cammilluzzi E ,Antimi M ,Terzoli E ,et al . Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol. 2003;21:3462-8. [PMID:12972521 ] CrossrefMedlineGoogle Scholar - 114.
Hornedo J ,Solá C ,Solano C ,López JJ ,Alonso S ,Lluch A ,et al ;SOLTI Group . The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period. Bone Marrow Transplant. 2002;29:737-43. [PMID:12040470 ] CrossrefMedlineGoogle Scholar - 115.
Little MA ,Morland B ,Chisholm J ,Hole A ,Shankar A ,Devine T ,et al . A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Med Pediatr Oncol. 2002;38:98-103. [PMID:11813173 ] CrossrefMedlineGoogle Scholar - 116.
Long HJ ,Rayson S ,Podratz KC ,Abu-Ghazaleh S ,Suman V ,Hartmann LC ,et al . Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature. Am J Clin Oncol. 2002;25:547-51. [PMID:12477995 ] CrossrefMedlineGoogle Scholar - 117.
Osby E ,Björkholm M ,Lundahl J ,Forslid J . Granulocyte function in elderly patients receiving chemotherapy for aggressive non-Hodgkin's lymphoma. Effect of granulocyte colony-stimulating factor. Eur J Intern Med. 2002;13:448. [PMID:12384135 ] CrossrefMedlineGoogle Scholar - 118.
Patte C ,Laplanche A ,Bertozzi AI ,Baruchel A ,Frappaz D ,Schmitt C ,et al . Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology. J Clin Oncol. 2002;20:441-8. [PMID:11786572 ] MedlineGoogle Scholar - 119.
Bradstock K ,Matthews J ,Young G ,Lowenthal R ,Baxter H ,Arthur C ,et al ;Australian Leukaemia Study Group . Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia. 2001;15:1331-8. [PMID:11516093 ] CrossrefMedlineGoogle Scholar - 120.
Goldstone AH ,Burnett AK ,Wheatley K ,Smith AG ,Hutchinson RM ,Clark RE ;Medical Research Council Adult Leukemia Working Party . Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302-11. [PMID:11520775 ] CrossrefMedlineGoogle Scholar - 121.
Trigg ME ,Peters C ,Zimmerman MB . Administration of recombinant human granulocyte-macrophage colony-stimulating factor to children undergoing allogeneic marrow transplantation: a prospective, randomized, double-masked, placebo-controlled trial. Pediatr Transplant. 2000;4:123-31. [PMID:11272605 ] CrossrefMedlineGoogle Scholar - 122.
Usuki K ,Urabe A . Safety of G-CSF in remission induction therapy in adult de novo acute myelogenous leukemia (a randomized study). Biotherapy. 2000;14:563-5. Google Scholar - 123.
Piccirillo N ,Sica S ,Laurenti L ,Chiusolo P ,La Barbera EO ,Sorà F ,et al . Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. Bone Marrow Transplant. 1999;23:1245-50. [PMID:10414910 ] CrossrefMedlineGoogle Scholar - 124.
Dunlop DJ ,Eatock MM ,Paul J ,Anderson S ,Reed NS ,Soukop M ,et al . Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group. Clin Oncol (R Coll Radiol). 1998;10:107-14. [PMID:9610900 ] CrossrefMedlineGoogle Scholar - 125.
Feng F ,Zhou L . [Randomized controlled study of leucomax (recombinant human granulocyte-macrophage colony stimulating factor, rhGM-CSF) in the treatment of cancer chemotherapy-induced leucopenia]. Zhonghua Zhong Liu Za Zhi. 1998;20:451-3. [PMID:10920943 ] MedlineGoogle Scholar - 126.
Kawano Y ,Takaue Y ,Mimaya J ,Horikoshi Y ,Watanabe T ,Abe T ,et al . Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT. Blood. 1998;92:4040-6. [PMID:9834207 ] MedlineGoogle Scholar - 127.
Laver J ,Amylon M ,Desai S ,Link M ,Schwenn M ,Mahmoud H ,et al . Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study. J Clin Oncol. 1998;16:522-6. [PMID:9469336 ] CrossrefMedlineGoogle Scholar - 128.
Lee SM ,Radford JA ,Dobson L ,Huq T ,Ryder WD ,Pettengell R ,et al . Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Br J Cancer. 1998;77:1294-9. [PMID:9579836 ] CrossrefMedlineGoogle Scholar - 129.
Stöger H ,Samonigg H ,Krainer M ,Ploszczynski M ,Nirnberger G ,Maca S ,et al . Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor. Eur J Cancer. 1998;34:482-8. [PMID:9713297 ] CrossrefMedlineGoogle Scholar - 130.
McQuaker IG ,Hunter AE ,Pacey S ,Haynes AP ,Iqbal A ,Russell NH . Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol. 1997;15:451-7. [PMID:9053465 ] CrossrefMedlineGoogle Scholar - 131.
van Pelt LJ ,de Craen AJ ,Langeveld NE ,Weening RS . Granulocyte-macrophage colony-stimulating factor (GM-CSF) ameliorates chemotherapy-induced neutropenia in children with solid tumors. Pediatr Hematol Oncol. 1997;14:539-45. [PMID:9383806 ] CrossrefMedlineGoogle Scholar - 132.
Zinzani PL ,Pavone E ,Storti S ,Moretti L ,Fattori PP ,Guardigni L ,et al . Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood. 1997;89:3974-9. [PMID:9166835 ] MedlineGoogle Scholar - 133.
Magrath I ,Adde M ,Shad A ,Venzon D ,Seibel N ,Gootenberg J ,et al . Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925-34. [PMID:8622041 ] CrossrefMedlineGoogle Scholar - 134.
Muhonen T ,Jantunen I ,Pertovaara H ,Voutilainen L ,Maiche A ,Blomqvist C ,et al . Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. Am J Clin Oncol. 1996;19:232-4. [PMID:8638531 ] CrossrefMedlineGoogle Scholar - 135.
Paterakis GS ,Tsavaris N ,Loukopoulos D . The effect of GM-CSF on reticulocytes, haemoglobin and haematocrit in patients receiving chemotherapy for solid tumours. Clin Lab Haematol. 1996;18:7-12. [PMID:9118614 ] CrossrefMedlineGoogle Scholar - 136.
Shi YK ,He XH ,Wang ZP . Clinical study of low dose granocyte (recombinant human granulocyte colony-stimulating factor, rhG-CSF, Lenograstim) on neutropenia induced by chemotherapy with CD regimen on lung cancer patients. Chinese Journal of Clinical Oncology. 1996;23:873-6. Google Scholar - 137.
Vannucchi AM ,Bosi A ,Ieri A ,Guidi S ,Saccardi R ,Lombardini L ,et al . Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. Bone Marrow Transplant. 1996;17:527-31. [PMID:8722349 ] MedlineGoogle Scholar - 138.
Welte K ,Reiter A ,Mempel K ,Pfetsch M ,Schwab G ,Schrappe M ,et al . A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group. Blood. 1996;87:3143-50. [PMID:8605328 ] CrossrefMedlineGoogle Scholar - 139.
Bergmann L ,Karakas T ,Knuth A ,Lautenschläger G ,Mitrou PS ,Hoelzer D . Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma—a randomised pilot study. Eur J Cancer. 1995;31A:2164-8. [PMID:8652236 ] CrossrefMedlineGoogle Scholar - 140.
Burdach SE ,Müschenich M ,Josephs W ,Frisch J ,Schulz G ,Jürgens H ,et al . Granulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Results of a prospective randomized study. Cancer. 1995;76:510-6. [PMID:8625134 ] CrossrefMedlineGoogle Scholar - 141.
Chevallier B ,Chollet P ,Merrouche Y ,Roche H ,Fumoleau P ,Kerbrat P ,et al . Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol. 1995;13:1564-71. [PMID:7541448 ] CrossrefMedlineGoogle Scholar - 142.
Chi KH ,Chen CH ,Chan WK ,Chow KC ,Chen SY ,Yen SH ,et al . Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 1995;13:2620-8. [PMID:7595716 ] CrossrefMedlineGoogle Scholar - 143.
Dibenedetto SP ,Ragusa R ,Ippolito AM ,Lo Nigro L ,Di Cataldo A ,D'Amico S ,et al . Assessment of the value of treatment with granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a randomized clinical trial. Eur J Haematol. 1995;55:93-6. [PMID:7543060 ] CrossrefMedlineGoogle Scholar - 144.
Hansen F ,Stenbygaard L ,Skovsgaard T . Effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hematologic toxicity induced by high-dose chemotherapy in patients with metastatic breast cancer. Acta Oncol. 1995;34:919-24. [PMID:7492381 ] CrossrefMedlineGoogle Scholar - 145.
Katano M ,Nakamura M ,Matsuo T ,Iyama A ,Hisatsugu T . Effect of granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced oral mucositis. Surg Today. 1995;25:202-6. [PMID:7543781 ] CrossrefMedlineGoogle Scholar - 146.
Logothetis CJ ,Finn LD ,Smith T ,Kilbourn RG ,Ellerhorst JA ,Zukiwski AA ,et al . Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol. 1995;13:2272-7. [PMID:7666085 ] CrossrefMedlineGoogle Scholar - 147.
Ardizzoni A ,Venturini M ,Sertoli MR ,Giannessi PG ,Brema F ,Danova M ,et al . Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer. Br J Cancer. 1994;69:385-91. [PMID:8297739 ] CrossrefMedlineGoogle Scholar - 148.
Eguchi K ,Kabe J ,Kudo S ,Mano K ,Morinari H ,Nakada K ,et al . Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancer. Cancer Chemother Pharmacol. 1994;34:37-43. [PMID:8174201 ] CrossrefMedlineGoogle Scholar - 149.
Eguchi K ,Etou H ,Miyachi S ,Morinari H ,Nakada K ,Noda K ,et al . A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer. Eur J Cancer. 1994;30A:188-94. [PMID:7512356 ] CrossrefMedlineGoogle Scholar - 150.
Engelhard M ,Gerhartz H ,Brittinger G ,Engert A ,Fuchs R ,Geiseler B ,et al . Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF. Ann Oncol. 1994;5Suppl 2 123-5. [PMID:7515644 ] CrossrefMedlineGoogle Scholar - 151.
Gebbia V ,Valenza R ,Testa A ,Cannata G ,Borsellino N ,Gebbia N . A prospective randomized trial of thymopentin versus granulocyte—colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy. Anticancer Res. 1994;14:731-4. [PMID:7516641 ] MedlineGoogle Scholar - 152.
Hamm J ,Schiller JH ,Cuffie C ,Oken M ,Fisher RI ,Shepherd F ,et al . Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma. J Clin Oncol. 1994;12:2667-76. [PMID:7989942 ] CrossrefMedlineGoogle Scholar - 153.
Hiraoka A ,Masaoka T ,Mizoguchi H ,Asano S ,Kodera Y ,Kitamura K ,et al . Recombinant human non-glycosylated granulocyte-macrophage colony-stimulating factor in allogeneic bone marrow transplantation: double-blind placebo-controlled phase III clinical trial. Jpn J Clin Oncol. 1994;24:205-11. [PMID:8072199 ] MedlineGoogle Scholar - 154.
Rampling R ,Steward W ,Paul J ,Macham MA ,Harvey E ,Eckley D . rhGM-CSF ameliorates neutropenia in patients with malignant glioma treated with BCNU. Br J Cancer. 1994;69:541-5. [PMID:8123485 ] CrossrefMedlineGoogle Scholar - 155.
Shi YK ,Sun Y ,Su M . Clinical study of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced leukopenia. Chinese Journal of Clinical Oncology. 1994;9:356-9. Google Scholar - 156.
Shi YK ,Feng FY ,Sun Y . Clinical study of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on leucopenia induced by chemotherapy with CE regimen on lung cancer patients. Chinese Journal of Clinical Oncology. 1994;33:739-42. Google Scholar - 157.
Spitzer G ,Adkins DR ,Spencer V ,Dunphy FR ,Petruska PJ ,Velasquez WS ,et al . Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol. 1994;12:661-70. [PMID:7512124 ] CrossrefMedlineGoogle Scholar - 158.
Gebbia V ,Testa A ,Valenza R ,Borsellino N ,Cipolla C ,Cannata G ,et al . A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. J Chemother. 1993;5:186-90. [PMID:7690396 ] CrossrefMedlineGoogle Scholar - 159.
Kaku K ,Takahashi M ,Moriyama Y ,Nakahata T ,Masaoka T ,Yoshida Y ,et al . Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial. Leuk Lymphoma. 1993;11:229-38. [PMID:8260897 ] CrossrefMedlineGoogle Scholar - 160.
Ohno R ,Tomonaga M ,Ohshima T ,Masaoka T ,Asou N ,Oh H ,et al . A randomized, controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. Japan Adult Leukemia Study Group. Int J Hematol. 1993;58:73-81. [PMID:7693029 ] MedlineGoogle Scholar - 161.
Trillet-Lenoir V ,Green J ,Manegold C ,Von Pawel J ,Gatzemeier U ,Lebeau B ,et al . Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A:319-24. [PMID:7691119 ] CrossrefMedlineGoogle Scholar - 162.
Anderson H ,Gurney H ,Thatcher N ,Swindell R ,Scarffe JH ,Weiner J . Recombinant human GM-CSF in small cell lung cancer: a phase I/II study. Recent Results Cancer Res. 1991;121:155-61. [PMID:1650015 ] CrossrefMedlineGoogle Scholar - 163.
de Vries EG ,Biesma B ,Willemse PH ,Mulder NH ,Stern AC ,Aalders JG ,et al . A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res. 1991;51:116-22. [PMID:1988077 ] MedlineGoogle Scholar - 164.
Havemann K ,Klausmann M ,Wolf M ,Fischer JR ,Drings P ,Oster W . Effect of rhGM-CSF on haematopoietic reconstitution after chemotherapy in small-cell lung cancer. J Cancer Res Clin Oncol. 1991;117Suppl 4 S203-7. [PMID:1665493 ] CrossrefMedlineGoogle Scholar - 165.
Kotake T ,Miki T ,Akaza H ,Kubota Y ,Nishio Y ,Matsumura Y ,et al . Effect of recombinant granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer. Cancer Chemother Pharmacol. 1991;27:253-7. [PMID:1705488 ] CrossrefMedlineGoogle Scholar - 166.
Liberati AM ,Cinieri S ,Schippa M ,Di Clemente F ,Filippo S ,Grignani F . GM-CSF: clinical trials in non-Hodgkin's lymphoma patients with chemotherapy induced leucopenia. Leukemia. 1991;5Suppl 1 119-22. [PMID:1890860 ] MedlineGoogle Scholar - 167.
Jost LM ,Pichert G ,Stahel RA . Placebo controlled phase I/II study of subcutaneous GM-CSF in patients with germ cell tumors undergoing chemotherapy. Ann Oncol. 1990;1:439-42. [PMID:1707298 ] CrossrefMedlineGoogle Scholar - 168.
Oyama A ,Ota K ,Asano S ,Takaku F ,Yoshida Y ,Uzuka Y ,et al . [A double-blind, cross-over clinical trial of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma]. Nippon Gan Chiryo Gakkai Shi. 1990;25:2533-48. [PMID:1702132 ] MedlineGoogle Scholar - 169.
Powles R ,Smith C ,Milan S ,Treleaven J ,Millar J ,McElwain T ,et al . Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial. Lancet. 1990;336:1417-20. [PMID:1978880 ] CrossrefMedlineGoogle Scholar
Author, Article, and Disclosure Information
Affiliations:
From the University of Toronto, The Hospital for Sick Children, and University Health Network, Toronto, Ontario, Canada.
Grant Support: In part by a career development award with the Canadian Child Health Clinician Scientist Training Program, a strategic program with the Canadian Institutes of Health Research (Dr. Sung).
Disclosures: None disclosed.
Corresponding Author: Lillian Sung, MD, PhD, Division of Haematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada; e-mail, lillian.
Current Author Addresses: Drs. Sung and Nathan: Division of Haematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.
Dr. Alibhai: Toronto General Hospital, Room EN 14-214, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada.
Dr. Tomlinson: Toronto General Hospital, Eaton Building East, Room 238, 13th Floor, 200 Elizabeth Street, Ontario M5G 2C4, Canada.
Dr. Beyene: Child Health Evaluative Sciences, Research Institute of The Hospital for Sick Children, Room 1206, 123 Edward Street, Toronto, Ontario M5G 1E2, Canada.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
*All comments submitted after October 1, 2021 and selected for publication will be published online only.